Efficacy and safety of once weekly dulaglutide and once daily insulin glargine treatment at 52 weeks in patients with type 2 diabetes (T2DM) in the Assessment of Weekly AdministRation of dulaglutide in Diabetes-2 (AWARD-2) study, stratified by duration of diabetes (< 5 years, ≥5 to < 10 years, ≥10 years)

Introduction: We determined the impact of duration of diabetes (DoD) on the efficacy and safety of dulaglutide and insulin glargine treatment in patients with T2DM.